FY2017 EPS Estimates for Reata Pharmaceuticals, Inc. (RETA) Reduced by Leerink Swann
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) – Analysts at Leerink Swann dropped their FY2017 earnings per share (EPS) estimates for Reata Pharmaceuticals in a report issued on Tuesday. Leerink Swann analyst J. Schwartz now anticipates that the company will post earnings of ($1.85) per share for the year, down from their previous forecast of ($1.73). Leerink Swann has a “Outperform” rating and a $43.00 price target on the stock. Leerink Swann also issued estimates for Reata Pharmaceuticals’ Q4 2017 earnings at ($0.51) EPS, FY2018 earnings at ($2.20) EPS and FY2019 earnings at ($2.24) EPS.
Other research analysts also recently issued reports about the stock. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $61.00 price target (up from $55.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, July 26th. Robert W. Baird reissued an “outperform” rating and set a $47.00 price objective (up from $43.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. ValuEngine upgraded shares of Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. Cowen and Company restated a “buy” rating on shares of Reata Pharmaceuticals in a report on Tuesday, November 14th. Finally, Zacks Investment Research cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Two research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $54.71.
Reata Pharmaceuticals (NASDAQ:RETA) opened at $24.63 on Friday. Reata Pharmaceuticals has a one year low of $18.51 and a one year high of $40.88. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of -0.09.
Reata Pharmaceuticals (NASDAQ:RETA) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.11). The business had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $12.54 million. The company’s quarterly revenue was up .0% compared to the same quarter last year.
In other news, Director James Edward Bass purchased 3,888 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were bought at an average price of $24.02 per share, for a total transaction of $93,389.76. Following the purchase, the director now directly owns 52,089 shares in the company, valued at approximately $1,251,177.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 62.40% of the company’s stock.
A number of large investors have recently modified their holdings of the business. Emerald Advisers Inc. PA raised its position in Reata Pharmaceuticals by 40.1% in the 3rd quarter. Emerald Advisers Inc. PA now owns 569,416 shares of the company’s stock worth $17,709,000 after buying an additional 162,990 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its position in Reata Pharmaceuticals by 60.9% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 473,051 shares of the company’s stock worth $14,712,000 after buying an additional 179,124 shares during the last quarter. FMR LLC raised its position in Reata Pharmaceuticals by 74.4% in the 2nd quarter. FMR LLC now owns 414,491 shares of the company’s stock worth $13,114,000 after buying an additional 176,885 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Reata Pharmaceuticals by 109.6% during the 2nd quarter. Vanguard Group Inc. now owns 295,540 shares of the company’s stock valued at $9,350,000 after purchasing an additional 154,515 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Reata Pharmaceuticals by 78.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 232,562 shares of the company’s stock valued at $7,359,000 after purchasing an additional 101,969 shares during the last quarter. 17.43% of the stock is owned by institutional investors and hedge funds.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.